Daewoong Develops Mass Production of Mini Janggi 'Organoid'

Innovation in Regenerative Medicine
Aiming for Global Commercialization through Localization

Daewoong announced on the 13th that it has been selected for the '2024 Material and Component Technology Development Project' led by the Ministry of Trade, Industry and Energy, with the project titled 'Development of Mass Production Technology for Organoid Regenerative Therapeutics,' which is recognized as a core technology in the field of regenerative medicine.

Organoids are three-dimensional tissues created to mimic organs within the human body. Using these organoids for regenerating a patient's damaged tissues or organs is called 'organoid regenerative therapeutics.' They are mainly applied to patients with impaired functions of major organs or tissues such as the heart, liver, and kidneys, helping organ regeneration and can be used for treating intractable diseases that are difficult to cure. For this reason, organoids are regarded as 'miniature human organs' and an 'innovation in regenerative medicine' that revives damaged life.

This project consists of a total of three sub-projects. As the lead company for Sub-project 1, Daewoong aims to develop core materials such as culture vessels enabling mass cultivation, high-quality extracellular matrix (ECM), growth factors, and additives. It supports research by providing proteins and chemicals such as growth hormones and verifies commercialization potential through performance evaluation of the materials. Additionally, in cooperation with Sub-projects 2 and 3, Daewoong plans to develop an automated production process capable of automatically managing the culture environment and precisely dispensing special media and reagents, optimizing organoid growth through real-time quality monitoring and data analysis, thereby improving productivity and quality.

Daewoong has developed innovative products incorporating bio-technology, starting with 'Easyef External Solution,' the first domestic bio new drug for diabetic foot ulcers, followed by the botulinum toxin 'Nabota,' and the bone substitute 'Novosis' loaded with recombinant human bone morphogenetic protein-2 (rhBMP-2). The company also has experience in stem cell research and development and operates the GMP-certified Yongin Bio Center capable of producing high-quality advanced biopharmaceuticals.

Jimin Yoo, Head of Daewoong Pharmaceutical Bio R&D Center, stated, "This project will enable the mass production of high-quality organoids," adding, "Through this project, we plan not only to develop technology but also to accelerate the global commercialization of organoid regenerative therapeutics."